NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Oncotelic Therapeutics' Sapu003 IV Formulation Reduces GI Exposure to Everolimus
TL;DR
Oncotelic's Sapu003 offers a competitive edge by reducing gastrointestinal side effects up to 67-fold compared to oral everolimus, potentially improving patient compliance and market positioning.
Oncotelic's intravenous Sapu003 formulation limits gastrointestinal tissue levels to 36-48 times plasma levels, representing a 67-fold reduction from oral dosing's extreme gut exposure of 2,448 times plasma.
This development could make cancer treatment more tolerable for patients, potentially improving quality of life during therapy and advancing oncology care.
Oncotelic's new formulation transforms drug delivery, shifting from extreme gut accumulation to targeted systemic exposure while maintaining the drug's metabolic profile.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics announced new pharmacokinetic and tissue-distribution data showing that its intravenous Sapu003 formulation of everolimus dramatically reduces gastrointestinal drug accumulation compared with oral everolimus, with reductions of up to 67-fold.
While oral everolimus drives extreme gut exposure up to 2,448× plasma levels in the stomach, IV Sapu003 limits GI tissue levels to just 36–48× plasma, representing reductions of up to 67-fold.
The company stated that this shift may improve tolerability, maintain the drug's intrinsic metabolic profile, and provide more consistent systemic exposure.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products, with a mission to address high-unmet-need cancers and rare pediatric indications.
Oncotelic Therapeutics owns 45% of the Sapu Nano joint venture, which is advancing its own pipeline of drug candidates that complement Oncotelic's strategic position in oncology and rare disease therapeutics.
Sapu003 is described as an intravenous Deciparticle (TM) formulation of everolimus, which is the specific technology that enables the reduced gastrointestinal exposure compared to oral dosing.
The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.
BioMedWire is a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences sectors that published this announcement as part of its distribution services.
The full press release can be viewed at https://ibn.fm/dVPuX.
Dr. Vuong Trieu, Oncotelic's CEO, has filed more than 150 patent applications and holds 39 issued U.S. patents, contributing significantly to the company's robust portfolio of inventions.
Curated from InvestorBrandNetwork (IBN)
